Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib and Olaparib in Advanced Solid Tumors
NCT03162627Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2017
- Primary completion
- Aug 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selumetinib and olaparib in solid tumor, ovarian cancer and endometrial cancer (EC) (5 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Aug 2017; status: active, not recruiting.
02
Drugs
selumetinibolaparib
03
Conditions
solid tumorovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT03162627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162627.